A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer

Inclusion Criteria: * Age \>= 18 years of age * Histologically documented breast cancer (hormone receptor (ER/PR) status may be either positive or negative) with or without metastatic disease. * HER-2(+) as determined by one of the following measurements. NOTE: HER-2(+) assessment may have been on initial diagnosis and need not be repeated for metastatic lesions * Immunohistochemistry (IHC) 3+, or * FISH + (HER-2 gene signal to centromere 17 signal \>2) * No transfusion dependent patients and no transfusion within 30 days of leukopheresis * Documented labs within 7 days of donation consisting of: * WBC \> 4.0 K/ul \& \< 11.0 K/ul * platelet count \> 150,000/mm3 * hemoglobin \> 11.0 g/dl. * Hematocrit \> 33 % * Weight \> 110 lbs * No blood donation in last 8 weeks (blood samples taken for standard of care less then 30 cc/week are acceptable) * Patients must not have active or unresolved infection. * No cold or flu sympton at time of donation * No prior myocardial infarction or active cardiac disease (e.g. congestive heart failure, clinically significant cardiac valvular disease or arrhythmia requiring medications, angina pectoris, uncontrolled hypertension, clinically significant pericardial effusion) * All patients must give signed written informed consent. * ECOG Performance Score of 0 or 1. * Women of childbearing potential must have a negative serum or urine pregnancy test Exclusion Criteria: * The presence of another active malignancy * Pregnant, lactating, or nursing * Patients with prior myocardial infarction or active cardiac disease (e.g. congestive heart failure, clinically significant cardiac valvular disease or arrhythmia requiring medications, angina pectoris, uncontrolled hypertension, clinically significant pericardial effusion)